chlortalidone ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
625 77-36-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clortalidone
  • phthalamudine
  • chlorphthalidolone
  • chlorthalidone
  • chlorthalidon
  • chlortalidone
A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
  • Molecular weight: 338.76
  • Formula: C14H11ClN2O4S
  • CLOGP: 0.45
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 109.49
  • ALOGS: -3.81
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
25 mg O
25 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.12 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 65 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.46 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 3.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.24 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 36 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 7, 1960 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 154.53 13.97 142 11436 111758 63365686
Hypokalaemia 61.78 13.97 85 11493 103719 63373725
Pneumonia viral 59.46 13.97 29 11549 7893 63469551
Cardiac murmur 52.87 13.97 33 11545 14519 63462925
Presyncope 51.95 13.97 42 11536 27743 63449701
Blood pressure increased 49.24 13.97 98 11480 161964 63315480
Breath sounds abnormal 47.91 13.97 28 11550 10945 63466499
Systemic infection 37.82 13.97 18 11560 4642 63472802
Milk-alkali syndrome 36.33 13.97 11 11567 817 63476627
Myxoedema coma 33.67 13.97 9 11569 426 63477018
Poor personal hygiene 31.13 13.97 8 11570 324 63477120
Wheezing 30.44 13.97 59 11519 95536 63381908
Eosinophilia 29.63 13.97 28 11550 22728 63454716
Diarrhoea infectious 29.20 13.97 10 11568 1101 63476343
Angle closure glaucoma 29.09 13.97 12 11566 2207 63475237
Nasal congestion 27.94 13.97 46 11532 65614 63411830
Chronic obstructive pulmonary disease 26.78 13.97 44 11534 62642 63414802
Renal impairment 26.28 13.97 53 11525 88302 63389142
Blood potassium decreased 25.86 13.97 35 11543 41991 63435453
Hyperlactacidaemia 23.10 13.97 11 11567 2838 63474606
Catastrophic reaction 22.81 13.97 4 11574 23 63477421
Synovitis 21.56 13.97 4 11574 186914 63290530
Treatment failure 21.43 13.97 5 11573 199038 63278406
Joint abscess 20.36 13.97 6 11572 406 63477038
Asthma 20.17 13.97 60 11518 127501 63349943
Strabismus 20.16 13.97 9 11569 2005 63475439
Cockroach allergy 19.30 13.97 4 11574 61 63477383
Blood glucose increased 18.94 13.97 45 11533 83711 63393733
Upper respiratory tract infection 18.46 13.97 44 11534 82003 63395441
Nodal rhythm 18.13 13.97 8 11570 1735 63475709
Productive cough 17.71 13.97 37 11541 63171 63414273
Toxicity to various agents 17.25 13.97 12 11566 247238 63230206
Abdominal discomfort 17.11 13.97 20 11558 320865 63156579
Drug interaction 16.52 13.97 84 11494 229047 63248397
Discomfort 16.51 13.97 5 11573 167369 63310075
Oedema peripheral 16.21 13.97 73 11505 189438 63288006
Systemic lupus erythematosus 16.15 13.97 9 11569 208909 63268535
Contraindicated product administered 15.94 13.97 10 11568 217638 63259806
Peripheral swelling 15.49 13.97 92 11486 265850 63211594
Hepatic enzyme increased 15.23 13.97 9 11569 202319 63275125
Hypervitaminosis 15.07 13.97 3 11575 37 63477407
Cough 15 13.97 98 11480 292645 63184799
Anaemia of malignant disease 14.78 13.97 5 11573 530 63476914
Drug intolerance 14.64 13.97 21 11557 308640 63168804
Iron deficiency anaemia 14.41 13.97 18 11560 19951 63457493
Renal artery stenosis 14.36 13.97 7 11571 1902 63475542

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Meningitis aseptic 108.93 16.80 37 7906 3187 34945801
Renal artery stenosis 96.67 16.80 31 7912 2230 34946758
Hyponatraemia 94.93 16.80 105 7838 82586 34866402
Rectal prolapse 94.35 16.80 22 7921 470 34948518
Renal cyst haemorrhage 88.63 16.80 22 7921 617 34948371
Intraductal papillary mucinous neoplasm 82.21 16.80 20 7923 515 34948473
SARS-CoV-2 antibody test positive 81.52 16.80 19 7924 405 34948583
Hypokalaemia 79.30 16.80 81 7862 58133 34890855
Abdominal wall haemorrhage 73.67 16.80 18 7925 472 34948516
Vena cava injury 69.43 16.80 16 7927 324 34948664
Carotid arteriosclerosis 65.43 16.80 22 7921 1836 34947152
Delayed graft function 61.58 16.80 22 7921 2199 34946789
Vascular anastomotic haemorrhage 61.25 16.80 14 7929 273 34948715
Perineal cyst 56.61 16.80 13 7930 259 34948729
Aortic dilatation 54.97 16.80 18 7925 1383 34947605
Mean cell volume increased 53.98 16.80 22 7921 3147 34945841
Hyperparathyroidism secondary 52.98 16.80 18 7925 1550 34947438
Vascular compression 52.42 16.80 13 7930 363 34948625
Actinic keratosis 49.33 16.80 23 7920 4544 34944444
Aortic arteriosclerosis 49.00 16.80 23 7920 4613 34944375
Diverticulum intestinal 48.93 16.80 22 7921 3999 34944989
Hepatosplenomegaly 48.17 16.80 22 7921 4147 34944841
Left ventricular hypertrophy 47.30 16.80 27 7916 8103 34940885
Intervertebral disc space narrowing 47.30 16.80 15 7928 1040 34947948
Chronic kidney disease 46.63 16.80 52 7891 41158 34907830
Choroidal effusion 44.35 16.80 10 7933 183 34948805
Fibrillary glomerulonephritis 43.86 16.80 8 7935 46 34948942
Spinal stenosis 43.27 16.80 22 7921 5247 34943741
Restless legs syndrome 41.38 16.80 25 7918 8329 34940659
Blood 25-hydroxycholecalciferol decreased 41.04 16.80 10 7933 259 34948729
Spinal osteoarthritis 40.68 16.80 24 7919 7659 34941329
Glycosylated haemoglobin increased 39.00 16.80 27 7916 11333 34937655
Swelling of eyelid 38.50 16.80 13 7930 1098 34947890
Presyncope 38.40 16.80 33 7910 19026 34929962
Activated partial thromboplastin time prolonged 35.46 16.80 23 7920 8672 34940316
Hepatic steatosis 35.39 16.80 31 7912 18331 34930657
Blood potassium increased 34.12 16.80 29 7914 16466 34932522
Vitamin D decreased 32.94 16.80 16 7927 3460 34945528
Arteriosclerosis 31.01 16.80 24 7919 11944 34937044
Haemorrhoids 30.92 16.80 26 7917 14549 34934439
Squamous cell carcinoma of skin 30.80 16.80 23 7920 10858 34938130
Dizziness 29.01 16.80 112 7831 218409 34730579
Bradycardia 28.74 16.80 57 7886 75361 34873627
Atrioventricular block first degree 27.04 16.80 17 7926 6075 34942913
Benign prostatic hyperplasia 26.99 16.80 24 7919 14471 34934517
Complications of transplanted kidney 23.36 16.80 14 7929 4595 34944393
Basal cell carcinoma 22.55 16.80 25 7918 19633 34929355
Blood pressure fluctuation 22.16 16.80 28 7915 25221 34923767
Vertigo 21.90 16.80 28 7915 25508 34923480
Hemiparaesthesia 21.39 16.80 5 7938 108 34948880
Gastrooesophageal reflux disease 21.33 16.80 34 7909 37890 34911098
Fear 20.81 16.80 18 7925 10458 34938530
Aortic valve incompetence 20.19 16.80 14 7929 5890 34943098
Red blood cell count decreased 19.06 16.80 28 7915 29062 34919926
Choroidal detachment 18.92 16.80 6 7937 416 34948572
Renal cyst 18.83 16.80 16 7927 9077 34939911
Incorrect dose administered 18.37 16.80 33 7910 40482 34908506
Amyloidosis 17.82 16.80 9 7934 2114 34946874
Angle closure glaucoma 17.52 16.80 7 7936 950 34948038

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyponatraemia 244.26 13.47 238 16268 177610 79550272
Hypokalaemia 116.16 13.47 146 16360 143894 79583988
Renal artery stenosis 109.48 13.47 37 16469 3445 79724437
Presyncope 94.78 13.47 74 16432 40980 79686902
Renal cyst haemorrhage 88.91 13.47 22 16484 670 79727212
SARS-CoV-2 antibody test positive 82.62 13.47 19 16487 420 79727462
Intraductal papillary mucinous neoplasm 76.11 13.47 20 16486 778 79727104
Vena cava injury 70.35 13.47 16 16490 336 79727546
Abdominal wall haemorrhage 69.11 13.47 18 16488 676 79727206
Rectal prolapse 64.00 13.47 22 16484 2156 79725726
Vascular anastomotic haemorrhage 62.54 13.47 14 16492 273 79727609
Carotid arteriosclerosis 59.73 13.47 22 16484 2634 79725248
Perineal cyst 57.95 13.47 13 16493 256 79727626
Delayed graft function 53.79 13.47 22 16484 3485 79724397
Aortic dilatation 52.06 13.47 18 16488 1794 79726088
Pneumonia viral 52.02 13.47 29 16477 9129 79718753
Left ventricular hypertrophy 49.18 13.47 30 16476 11161 79716721
Chronic kidney disease 48.46 13.47 64 16442 66090 79661792
Vascular compression 48.16 13.47 13 16493 561 79727321
Angle closure glaucoma 46.78 13.47 19 16487 2957 79724925
Cardiac murmur 46.54 13.47 33 16473 15791 79712091
Hyperparathyroidism secondary 45.33 13.47 18 16488 2642 79725240
Intervertebral disc space narrowing 45.11 13.47 16 16490 1719 79726163
Mean cell volume increased 44.49 13.47 23 16483 6230 79721652
Fibrillary glomerulonephritis 43.37 13.47 8 16498 55 79727827
Actinic keratosis 42.35 13.47 22 16484 6020 79721862
Hepatosplenomegaly 42.25 13.47 22 16484 6047 79721835
Aortic arteriosclerosis 42.01 13.47 25 16481 8893 79718989
Choroidal effusion 41.55 13.47 12 16494 665 79727217
Bradycardia 40.76 13.47 88 16418 135469 79592413
Blood 25-hydroxycholecalciferol decreased 38.30 13.47 10 16496 379 79727503
Diverticulum intestinal 37.64 13.47 23 16483 8582 79719300
Blood pressure increased 37.18 13.47 112 16394 211248 79516634
Blood potassium increased 36.03 13.47 37 16469 29238 79698644
Breath sounds abnormal 35.13 13.47 28 16478 15956 79711926
Arteriosclerosis 33.94 13.47 29 16477 18198 79709684
Glycosylated haemoglobin increased 32.55 13.47 29 16477 19231 79708651
Squamous cell carcinoma of skin 31.73 13.47 25 16481 14008 79713874
Spinal osteoarthritis 31.66 13.47 27 16479 16900 79710982
Hepatic steatosis 31.55 13.47 39 16467 37699 79690183
Benign prostatic hyperplasia 31.36 13.47 23 16483 11589 79716293
Oedema peripheral 30.55 13.47 118 16388 252170 79475712
Blood potassium decreased 29.53 13.47 42 16464 46470 79681412
Activated partial thromboplastin time prolonged 29.31 13.47 24 16482 14204 79713678
Milk-alkali syndrome 29.14 13.47 11 16495 1409 79726473
Meningitis aseptic 28.98 13.47 18 16488 6910 79720972
Myxoedema coma 27.85 13.47 9 16497 728 79727154
Renal impairment 27.15 13.47 83 16423 157700 79570182
Spinal stenosis 27.13 13.47 24 16482 15767 79712115
Dizziness 26.51 13.47 193 16313 526248 79201634
Poor personal hygiene 26.22 13.47 8 16498 536 79727346
Basal cell carcinoma 25.59 13.47 35 16471 37340 79690542
Syncope 25.13 13.47 88 16418 179361 79548521
Swelling of eyelid 24.22 13.47 13 16493 3798 79724084
Diarrhoea infectious 23.97 13.47 10 16496 1664 79726218
Vitamin D decreased 23.46 13.47 18 16488 9707 79718175
Systemic infection 23.41 13.47 18 16488 9734 79718148
Nasal congestion 23.34 13.47 50 16456 76502 79651380
Catastrophic reaction 22.30 13.47 4 16502 23 79727859
Restless legs syndrome 22.24 13.47 24 16482 20068 79707814
Iron deficiency anaemia 22.22 13.47 27 16479 25645 79702237
Febrile neutropenia 22.21 13.47 10 16496 230989 79496893
Acute kidney injury 22.02 13.47 183 16323 519221 79208661
Complications of transplanted kidney 20.41 13.47 14 16492 6352 79721530
Wheezing 19.72 13.47 61 16445 116603 79611279
Chronic obstructive pulmonary disease 19.69 13.47 50 16456 85369 79642513
Hyperlactacidaemia 19.60 13.47 13 16493 5582 79722300
Haemorrhoids 19.52 13.47 27 16479 29101 79698781
Treatment failure 18.68 13.47 6 16500 170480 79557402
Blood pressure inadequately controlled 18.43 13.47 13 16493 6164 79721718
Hemiparaesthesia 18.11 13.47 5 16501 235 79727647
Aortic valve incompetence 17.41 13.47 15 16491 9515 79718367
Strabismus 17.15 13.47 9 16497 2512 79725370
Choroidal detachment 17.05 13.47 6 16500 630 79727252
Renal cyst 17.01 13.47 18 16488 14714 79713168
Amyloidosis 16.55 13.47 9 16497 2697 79725185
Atrioventricular block 15.94 13.47 17 16489 14024 79713858
Atrioventricular block first degree 15.75 13.47 16 16490 12475 79715407
Inappropriate antidiuretic hormone secretion 15.59 13.47 23 16483 26290 79701592
Vertigo 15.47 13.47 40 16466 69042 79658840
Eosinophilia 15.44 13.47 31 16475 45314 79682568
Hypertensive crisis 15.05 13.47 20 16486 20750 79707132
Hypotension 14.99 13.47 148 16358 440169 79287713
Peripheral swelling 14.78 13.47 101 16405 269516 79458366
Hypervitaminosis 14.76 13.47 3 16503 36 79727846
Metabolic alkalosis 14.69 13.47 10 16496 4479 79723403
Spinal pain 14.66 13.47 17 16489 15375 79712507
Drug abuse 14.20 13.47 8 16498 162683 79565199
Joint abscess 14.10 13.47 5 16501 537 79727345
Blood glucose increased 14.07 13.47 54 16452 114921 79612961
Toxicity to various agents 13.89 13.47 43 16463 421497 79306385
Calcium ionised decreased 13.71 13.47 5 16501 582 79727300
Congenital aortic dilatation 13.63 13.47 3 16503 54 79727828
Nausea 13.47 13.47 275 16231 956921 78770961

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C03BA04 CARDIOVASCULAR SYSTEM
DIURETICS
LOW-CEILING DIURETICS, EXCL. THIAZIDES
Sulfonamides, plain
ATC C03BB04 CARDIOVASCULAR SYSTEM
DIURETICS
LOW-CEILING DIURETICS, EXCL. THIAZIDES
Sulfonamides and potassium in combination
ATC C03EA06 CARDIOVASCULAR SYSTEM
DIURETICS
DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION
Low-ceiling diuretics and potassium-sparing agents
FDA PE N0000175359 Increased Diuresis
FDA EPC N0000175420 Thiazide-like Diuretic
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004232 Diuretics
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D045283 Natriuretic Agents
MeSH PA D049993 Sodium Chloride Symporter Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Edema indication 267038008
Pulmonary Edema due to Chronic Heart Failure indication
Peripheral Edema due to Chronic Heart Failure indication
Diabetes insipidus off-label use 15771004 DOID:9409
Calcium renal calculus off-label use 427649000
Anuria contraindication 2472002 DOID:2983
Suicidal thoughts contraindication 6471006
Psoriasis contraindication 9014002 DOID:8893
Peptic ulcer contraindication 13200003 DOID:750
Hypercholesterolemia contraindication 13644009
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Electroconvulsive therapy contraindication 23835007
Complete atrioventricular block contraindication 27885002
Depressive disorder contraindication 35489007
Hyperuricemia contraindication 35885006 DOID:1920
Anaphylaxis contraindication 39579001
Hypokalemia contraindication 43339004
Diabetes mellitus type 2 contraindication 44054006 DOID:9352
Conduction disorder of the heart contraindication 44808001
Tear film insufficiency contraindication 46152009
End stage renal disease contraindication 46177005 DOID:784
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Chronic heart failure contraindication 48447003
Sinus bradycardia contraindication 49710005
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Cerebrovascular disease contraindication 62914000 DOID:6713
Ulcerative colitis contraindication 64766004 DOID:8577
Hypercalcemia contraindication 66931009 DOID:12678
Hypochloremic alkalosis contraindication 70134007
Oliguria contraindication 83128009
Epilepsy contraindication 84757009 DOID:1826
Cardiogenic shock contraindication 89138009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Asthma contraindication 195967001 DOID:2841
Acute pancreatitis contraindication 197456007 DOID:2913
Atrioventricular block contraindication 233917008 DOID:0050820
Raynaud's phenomenon contraindication 266261006
Calculus in biliary tract contraindication 266474003
Pregnancy, function contraindication 289908002
Severe chronic obstructive pulmonary disease contraindication 313299006
Surgical procedure contraindication 387713003
Chronic myocardial ischemia contraindication 413844008 DOID:3393
First Degree Atrioventricular Heart Block contraindication
Acutely Decompensated HF Requiring Parenteral Inotropic Therapy contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.63 acidic
pKa2 9.38 acidic
pKa3 13.47 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 40MG MEDOXOMIL;12.5MG EDARBYCLOR AZURITY N202331 Dec. 20, 2011 RX TABLET ORAL 7572920 Jan. 7, 2025 TREATMENT OF HYPERTENSION
EQ 40MG MEDOXOMIL;25MG EDARBYCLOR AZURITY N202331 Dec. 20, 2011 RX TABLET ORAL 7572920 Jan. 7, 2025 TREATMENT OF HYPERTENSION
EQ 40MG MEDOXOMIL;12.5MG EDARBYCLOR AZURITY N202331 Dec. 20, 2011 RX TABLET ORAL 9387249 July 1, 2031 TREATMENT OF HYPERTENSION
EQ 40MG MEDOXOMIL;25MG EDARBYCLOR AZURITY N202331 Dec. 20, 2011 RX TABLET ORAL 9387249 July 1, 2031 TREATMENT OF HYPERTENSION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Solute carrier family 12 member 3 Transporter INHIBITOR CHEMBL CHEMBL
Carbonic anhydrase 1 Enzyme Ki 6.46 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 6.71 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.64 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 8.35 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 6.04 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 8.05 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 8.55 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 4.96 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 5.87 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 5.38 CHEMBL
Carbonic anhydrase 2 Enzyme Kd 5.56 WOMBAT-PK
Carbonic anhydrase 13 Enzyme Ki 7.82 CHEMBL

External reference:

IDSource
4017887 VUID
N0000146240 NUI
D00272 KEGG_DRUG
2409 RXNORM
4017887 VANDF
CHEBI:3654 CHEBI
KLT PDB_CHEM_ID
CHEMBL1055 ChEMBL_ID
CHEMBL255014 ChEMBL_ID
7147 IUPHAR_LIGAND_ID
DB00310 DRUGBANK_ID
4364 MMSL
4432 MMSL
d00192 MMSL
002309 NDDF
387324004 SNOMEDCT_US
57893000 SNOMEDCT_US
D002752 MESH_DESCRIPTOR_UI
C0008294 UMLSCUI
1125 INN_ID
2732 PUBCHEM_CID
Q0MQD1073Q UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 0378-0213 TABLET 50 mg ORAL ANDA 25 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 0378-0222 TABLET 25 mg ORAL ANDA 25 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 0591-5782 TABLET 25 mg ORAL ANDA 18 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 0591-5783 TABLET 25 mg ORAL ANDA 18 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 0904-6900 TABLET 25 mg ORAL ANDA 21 sections
ATENOLOL AND CHLORTHALIDONE HUMAN PRESCRIPTION DRUG LABEL 2 10135-733 TABLET 25 mg ORAL ANDA 21 sections
ATENOLOL AND CHLORTHALIDONE HUMAN PRESCRIPTION DRUG LABEL 2 10135-734 TABLET 25 mg ORAL ANDA 21 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 16714-128 TABLET 25 mg ORAL ANDA 16 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 16714-128 TABLET 25 mg ORAL ANDA 16 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 16714-129 TABLET 50 mg ORAL ANDA 16 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 16714-129 TABLET 50 mg ORAL ANDA 16 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 16714-800 TABLET 25 mg ORAL ANDA 21 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 16714-801 TABLET 50 mg ORAL ANDA 21 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 16714-936 TABLET 25 mg ORAL ANDA 16 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 16714-936 TABLET 25 mg ORAL ANDA 16 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 16714-937 TABLET 25 mg ORAL ANDA 16 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 16714-937 TABLET 25 mg ORAL ANDA 16 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 21695-671 TABLET 25 mg ORAL ANDA 24 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 21695-743 TABLET 25 mg ORAL ANDA 18 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 21695-744 TABLET 25 mg ORAL ANDA 18 sections
Chlorthalidone Human Prescription Drug Label 1 27241-216 TABLET 25 mg ORAL ANDA 20 sections
Chlorthalidone Human Prescription Drug Label 1 27241-217 TABLET 50 mg ORAL ANDA 20 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 29300-333 TABLET 25 mg ORAL ANDA 19 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 29300-333 TABLET 25 mg ORAL ANDA 19 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 29300-334 TABLET 50 mg ORAL ANDA 19 sections
Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 1 29300-334 TABLET 50 mg ORAL ANDA 19 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 29300-400 TABLET 25 mg ORAL ANDA 17 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 29300-401 TABLET 25 mg ORAL ANDA 17 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 33261-942 TABLET 25 mg ORAL ANDA 18 sections
Atenolol and Chlorthalidone HUMAN PRESCRIPTION DRUG LABEL 2 43353-149 TABLET 25 mg ORAL ANDA 18 sections